ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PRAX
ALKS (78) AXSM (35) ABVX (54) ARWR (58) ⌘ Pro Terminal →

Praxis Precision Medicines Inc. (PRAX) — RQD Stock Rating Cockpit

$273.99 -4.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $271.41

Praxis Precision Medicines Inc. (PRAX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $7.98B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRAX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Praxis Precision Medicines Inc. (NASDAQ: PRAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $273.99 (-4.18% 1D, market cap $7.98B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PRAX ranks #283 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRAX compare to ALKS and AXSM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRAX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALKS (Alkermes plc) holds a B+ grade (78/100 RQD, P/E 31.5x, ROIC 14.0%, cap $7.61B) and AXSM (Axsome Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while ALKS leads on capital efficiency (14.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRAX?
▼

Per PRAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001689548), Praxis Precision Medicines Inc. generated $913.4M in revenue (+10578.8% YoY), -$303.0M in net income, and -$249.1M in free cash flow against $937.9M in total assets and $26.9M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $271.41 (-0.94%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510048
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk C
Cash (7)Whales (11)SEC (16)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
$412 Bull$262 Base$204 Bear
📬 FREE PRAX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRAX)Realized 20D OHLCV Swing Band: ±8.6%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY PRAX SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (33% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (23% of score)

20D Institutional Volume Accumulation (±8.6% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$239.02+7.3% Next Q
Q2 (-2Q)
43
Grade D$256.47+11.3% Next Q
Q3 (-1Q)
45
Grade D$285.48-4% Next Q
Current
48
Grade D$273.99-5.6% Hist 90D α
Trajectory: D (40) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRAX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRAX currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($296.31) and Max Pain ($287.69) forces dealer call-delta covering toward $412.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
54.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
26.00>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE50% OF RANGE
L: $154$273.99H: $393
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on PRAX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -3.09% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (42)

16/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like PRAX
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRAX)

  • ✓Walkthrough of PRAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PRAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.84%📐 HORIZONTAL RANGE
2026-11-03O $288.6H $288.6L $274.0C $274.0VOL 306.6K
RES: $416.2SUP: $222.6SMA50: $296.3SMA200: $314.5
$405.9$351.2$296.5$241.8$187.1RES $416.2SUP $222.6$274.02026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRAX Butterfly Map → + Track PRAX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.5%/yr Implied 5Y Growth

vs. +10578.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRAX)

Health Care Rank #283 of 1015 ⚔️ ALKS vs PRAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRAX vs. ALKS, AXSM, ABVX, ARWR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Praxis Precision Medicines Inc. (PRAX) ranks #283 by composite RQD confidence (48/100, grade D) and #125 by equity capitalization ($7.98B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while ALKS leads on capital efficiency and profitability with 14.0% ROIC and 86.7% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with PRAX at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRAX ACTIVE
Praxis Precision Medicines Inc.
D 48/100 — — -35.0% -4.18% $7.98B Benchmark Subject
ALKS
Alkermes plc
B+ 78/100 31.5x 86.7% 14.0% -0.99% $7.61B /alks-vs-prax →
AXSM
Axsome Therapeutics Inc.
D- 35/100 — — -21.9% -5.83% $7.57B /axsm-vs-prax →
ABVX
Abivax SA
D+ 54/100 32.8x — 9.9% -1.94% $7.56B /abvx-vs-prax →
ARWR
Arrowhead Pharmaceuticals Inc.
D+ 58/100 — — 11.1% -0.55% $8.46B /arwr-vs-prax →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001689548 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Praxis Precision Medicines Inc. (PRAX) reported GAAP revenue of $913.4M (+10578.8% vs. FY2024 revenue of $8.6M , and +37225.5% cumulative change since FY2023) , GAAP net income of -$303.0M, operating cash flow of -$249.1M, and free cash flow of -$249.1M (-89.1% YoY). On the balance sheet, PRAX closed FY2025 with $937.9M in total assets against $26.9M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $913.4M -$303.0M -$249.1M -$249.1M $937.9M $26.9M
FY2024 (FY) 2024-12-31 $8.6M -$183.0M -$131.8M -$131.8M $483.1M $16.9M
FY2023 (FY) 2023-12-31 $2.4M -$123.0M -$111.1M -$111.2M $4.43B $1.04B

3. PRAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Praxis Precision Medicines Inc. (NASDAQ: PRAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $273.99 (-4.18% 1D, market cap $7.98B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PRAX ranks #283 in composite RQD confidence.

How does PRAX compare to ALKS and AXSM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRAX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALKS (Alkermes plc) holds a B+ grade (78/100 RQD, P/E 31.5x, ROIC 14.0%, cap $7.61B) and AXSM (Axsome Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while ALKS leads on capital efficiency (14.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRAX?

Per PRAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001689548), Praxis Precision Medicines Inc. generated $913.4M in revenue (+10578.8% YoY), -$303.0M in net income, and -$249.1M in free cash flow against $937.9M in total assets and $26.9M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRAX trading relative to its 50-day, 200-day, and 52-week technical levels?

PRAX last traded at $273.99 (-4.18% on volume of 312,389 shares), positioning the stock -7.53% below its 50-day simple moving average ($296.31) and -12.87% below its 200-day simple moving average ($314.46). Across its 52-week range of $154.45 to $392.70, PRAX sits at the 50.2% percentile with a 14-day RSI of 54.5 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($250.43 to $297.55).

Direct Sub-Reports: PRAX RQD Cockpit PRAX 12M Forecast PRAX Earnings & Move PRAX Dividends & DRIP PRAX Insiders & 13F PRAX Whale Options PRAX Profit Sankey PRAX News & Why
ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ SEC XBRL & RQD VERIFIED

PRAX — Praxis Precision Medicines Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Praxis Precision Medicines Inc. (PRAX) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $273.99 (-4.18% 1D, market capitalization $7.98B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -3.09%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (16/20): Incorporates a 0.91x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.03x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Praxis Precision Medicines Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B. Per the recent news wire, the company has two medicines under FDA review and is discussing launch readiness for them. Per the financials, FY 2025 revenue is — and FY 2024 revenue is $8.6M, indicating the company has not yet established a meaningful commercial revenue base. — for how these medicines are sold or to which customers.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Praxis Precision Medicines Inc. (PRAX) reported $913.4M in annual revenue (up from $8.6M in FY2024, +10578.8% YoY) and -$303.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.4M revenue, -$123.0M net income) through FY2025, PRAX scaled operating cash flow to -$249.1M and free cash flow to -$249.1M, backed by $937.9M in total assets against $26.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 48/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -3.09% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $154.45 – $392.70 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 0.91x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided data.

  • Key Question #1: Can PRAX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $913.4M and free cash flow of -$249.1M, how will capital allocation balance growth reinvestment against $26.9M in total debt?
  • Key Question #3: How sensitive is PRAX's 33.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.91x)?

PRAX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Praxis Precision Medicines Inc. (PRAX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRAX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRAX Bull vs. Bear Conversation Board — What's Your Call at $273.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRAX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PRAX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $343.12 (+20.0%)
📌 Pinned Debate

Forensic balance sheet scores 16/20 with Altman Z of 26 and Debt/Equity of 0.03, plus $357.3M cash, giving the company substantial runw

Long PRAX at $285.93 targeting $343.12. Forensic balance sheet scores 16/20 with Altman Z of 26 and Debt/Equity of 0.03, plus $357.3M cash, giving the company substantial runway against its losses.. Institutional whale score is 11/20 and the risk/reward vs. the $154.45 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — PRAX's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $220.17 (-23.0%)
Spot @ $285.93

ROIC of -35% and FCF yield of -3.09% leave the Fundamental Cash Engine at 7/20, with FY 2025 FCF of -$249.1M and no reported revenue.

Fading this rally in PRAX at $285.93. ROIC of -35% and FCF yield of -3.09% leave the Fundamental Cash Engine at 7/20, with FY 2025 FCF of -$249.1M and no reported revenue.. With a beta of 0.91 and the stock sitting at $285.93 (52-wk range $154.45–$392.70), the easy multiple expansion is already priced in.

LIVE TAPE